ClinicalTrials.gg
CompletedNCT00035425Updated Dec 1, 2009

Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection

A Phase 3 interventional study of linezolid and vancomycin in Febrile Neutropenia, sponsored by Pfizer. Completed at 40 sites in 10 countries. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2009-12-01.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Febrile Neutropenia with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Febrile Neutropenia · United States.

Enrollment
7th of 12
120 · median 131
Started
2001
the only one that year
Phase 3
3 of 18
none open now
Registered
1st of 18
by date
Lead sponsor
3 of 18
Pfizer

Among the 18 studies in Febrile Neutropenia with a site in United States, this one is the 7th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2001, is one of 3 in phase 3, and was the 1st registered.

Febrile Neutropenia

147 studies on the registry are indexed under Febrile Neutropenia; 36 are open to participants now.

Browse Febrile Neutropenia studies →

Open to participants now

1 of the 18 studies in Febrile Neutropenia with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Febrile Neutropenia studies recruiting now, 11 (58%) set no upper age limit and 8 (42%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Febrile Neutropenia with a site in United States, or all of them as a file.
02

Study summary

This study will treat patients who have fever and neutropenia (after cancer chemotherapy) that is possibly due to a specific bacteria (gram positive bacteria).

03

Conditions studied

  • Febrile Neutropenia

Browse trials for

04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must have neutropenia (ANC less than 500) with fever (oral temp 38.3 C).

Patients must have a cancer with recent chemotherapy and risks factors for gram positive infections.

Exclusion criteria

Exclusion Criteria:

Patients with fever due to known causes. Patients with . Patients with recent bone marrow transplant. Patients with an infected indwelling catheter that cannot be removed. Patients who have received more than one day of another antibiotic before entering the trial.

Patients with endocarditis, osteomyelitis, meningitis, CNS infections.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    A.

    Patients will be stratified according to the use of prophylactic antibiotics. Both groups may receive open-label gram-negative coverage with either ceftazidime, aztreonam, and/or aminoglycosides (gentamicin, tobramycin, amikacin). Subjects will receive study medication intravenously every 12 hours for 7 to 28 days.

    Drug: linezolid

  • Experimental
    B.

    Drug: vancomycin

Interventions

  • 600mg every 12 hours

    Also known as: Zyvox

  • 1gm every 12 hours. The dose of vancomycin intravenously may be adjusted for renal function, but the patient must be able to receive a 300 mL volume of intravenous fluid at the assigned dosing times of every 12 hours.

06

What researchers measure

Primary outcomes

  1. Clinical efficacy of linezolid when administered intravenously as compared to intravenously administered vancomycin in the empiric treatment of oncology patients with febrile neutropenia with suspected gram-positive infections.

    Time frame: 7-28 days

Secondary outcomes

  1. Microbiologic outcome

    Time frame: 7-28 days

  2. Pathogen eradication (eradication rates of individual pathogens)

    Time frame: 7-28 days

  3. Defervescence (defined as Tmax orally or rectally)

    Time frame: 7-28 days

  4. Time to defervescence

    Time frame: 7-28 days

  5. Resolution of neutropenia (return of ANC to >500 cells/mm3)

    Time frame: 7-28 days

  6. Time to resolution of neutropenia

    Time frame: 7-28 days

  7. Mortality rate (survival at 7 days after the end of therapy)

    Time frame: 7-28 days

07

Study locations

40 sites
  • Pfizer Investigational Site
    Los Angeles, California 90033, United States
  • Pfizer Investigational Site
    Springfield, Illinois 62701-1014, United States
  • Pfizer Investigational Site
    Springfield, Illinois 62703, United States
  • Pfizer Investigational Site
    Springfield, Illinois 62769, United States
  • Pfizer Investigational Site
    Springfield, Illinois 62781, United States
  • Pfizer Investigational Site
    Bronx, New York 10461, United States
  • Pfizer Investigational Site
    Bronx, New York 10467, United States
  • Pfizer Investigational Site
    Houston, Texas 77030, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23226, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23229, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23249, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23294-4367, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23294, United States
  • Pfizer Investigational Site
    Federal Way, Washington 98003, United States
  • Pfizer Investigational Site
    Lakewood, Washington 98499, United States
  • Pfizer Investigational Site
    Tacoma, Washington 98405, United States
  • Pfizer Investigational Site
    Buenos Aires, 1094, Argentina
  • Pfizer Investigational Site
    Cordoba, 5000, Argentina
  • Pfizer Investigational Site
    Mendoza, 5500, Argentina
  • Pfizer Investigational Site
    Porto Alegre, RS 90020-090, Brazil
  • Pfizer Investigational Site
    Porto Alegre, RS 90610-000, Brazil
  • Pfizer Investigational Site
    Sao Paulo, SP 01509-900, Brazil
  • Pfizer Investigational Site
    São Paulo, SP 01409-902, Brazil
  • Pfizer Investigational Site
    São Paulo, 04024-002, Brazil
  • Pfizer Investigational Site
    São Paulo, 05651-901, Brazil
  • Pfizer Investigational Site
    Santiago, Chile
  • Pfizer Investigational Site
    Bogota, Bogota. DC NAP, Colombia
  • Pfizer Investigational Site
    Bogota, Bogota. DC, Colombia
  • Pfizer Investigational Site
    Medellin, Colombia
  • Pfizer Investigational Site
    Helsinki, FIN-00029 HYKS, Finland
  • Pfizer Investigational Site
    Zapopan, Jalisco 45173, Mexico
  • Pfizer Investigational Site
    Monterrey, Nuevo Leon C.P. 64000, Mexico
  • Pfizer Investigational Site
    Mexico D.f., C.P. 02990, Mexico
  • Pfizer Investigational Site
    Lahore, Punjab, Pakistan
  • Pfizer Investigational Site
    Karachi, 74800, Pakistan
  • Pfizer Investigational Site
    Lima, 13, Peru
  • Pfizer Investigational Site
    Lima, 34, Peru
  • Pfizer Investigational Site
    Caracas, Distrito Federal 1041, Venezuela
  • Pfizer Investigational Site
    Caracas, 1020, Venezuela
  • Pfizer Investigational Site
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2001 and a completion of Nov 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2002
First posted
May 6, 2002
Start
Nov 2001
CompletionActual
Nov 2002
Last update
Dec 1, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00035425
Lead sponsor
Pfizer
First posted
May 6, 2002
Start date
Nov 2001
Completion
Nov 2002
Last update
Dec 1, 2009

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Linezolid · Vancomycin

Start the discussion